Osthole

Osthole (Osthol): A Comprehensive Reference

1. Identity and Chemical Profile

Chemical Names and Classification

Osthole, also known as osthol, has the systematic chemical name 7-methoxy-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one and is a natural coumarin first derived from the Cnidium plant. It is the main active ingredient of the Chinese traditional herbal medicine Cnidium monnieri (L.) Cuss., with a molecular formula of C₁₅H₁₆O₃ and a molecular weight of 244.29.

Coumarin, with a 2H-benzopyran-2-one core structure, is considered the simplest form within a large class of naturally occurring phenolic substances; it was first isolated as a natural product from tonka beans by Vogel in 1820, and coumarins are widely distributed in higher plants, mostly from the Umbelliferae and Rutaceae families, as well as in bacteria and fungi. Osthole itself is classified as a prenylated coumarin, bearing a 3-methylbut-2-enyl (prenyl) side chain at the 8-position and a methoxy group at the 7-position of the coumarin scaffold.

Natural Sources and Botanical Origin

High content of osthole is found in the mature fruit of Cnidium monnieri (Fructus Cnidii), which is commonly applied in clinical practice of Traditional Chinese Medicine (TCM), while it is also widely found in other medicinal plants including Angelica, Archangelica, Citrus, and Clausena.

Cnidium monnieri (L.) Cusson ex Juss., also known as Monnier's snowparsley, is a flowering plant species in the genus Cnidium, also recognized under the common names Shechuangzi, Jashoshi, and Cnidii Fructus (Fruits of Cnidium). The coumarins osthol, imperatorin, and xanthotoxol can all be found in C. monnieri. The main active components in C. monnieri are coumarins — principally osthole — and volatile compounds, and these exhibit multiple pharmacological effects including anti-inflammatory, antibacterial, antioxidant, anti-tumor, and immune-regulating effects.

Cnidium monnieri is a species in the genus Cnidium, which contains approximately 11 to 35 species and belongs to the family Apiaceae (carrot family). The plant is a species of Umbelliferae plants, one of China's traditional medicinal herbs, widely distributed in China owing to its strong adaptability in fields.

Common Forms and Preparations

Osthole can be obtained via extraction and separation from plants or by total synthesis. Industrially, it is typically extracted from the dried fruits (Fructus Cnidii) of Cnidium monnieri using ethanol-based processes and is available as a standardized isolate with a defined purity level. Due to the low water solubility of osthole, which limits its potential clinical application, it has been incorporated into nanoparticle formulations such as polybutylcyanoacrylate (PBCA) nanoparticles by microemulsion polymerization to improve aqueous solubility.

Given its poor solubility in aqueous media and lack of organizational targeting, novel drug delivery methods have been designed to overcome these shortcomings. These include microemulsion systems, cyclodextrin inclusion complexes, nanoparticles, chitosan micelles, liposomes, and thermosensitive gel formulations. In its traditional form, the source herb is administered as the fruit, seed, and other plant parts, and it has been used in Traditional Chinese Medicine for thousands of years, often for skin conditions, being a common ingredient in Chinese lotions, creams, and ointments.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

High content of osthole is found in the mature fruit of Cnidium monnieri (Fructus Cnidii), which is commonly applied in clinical practice of Traditional Chinese Medicine (TCM); Fructus Cnidii was used to strengthen the immune system and improve male function, relieve rheumatic pain, and eliminate dampness, with most of these medicinal properties attributed to osthole as one of its major bioactive components.

In the framework of TCM, osthole is classified as a bioactive ingredient with the status of "emperor" in many TCM formulas, reflecting its primary therapeutic role within compound prescriptions. The classical TCM system employs the "Emperor–Minister–Assistant–Courier" model when combining herbs, and a modern research approach has sought to increase the intracerebral bioavailability of osthole by using borneol as a "courier," based on this classical compositional theory.

People take Cnidium by mouth for increasing sexual performance and sex drive, treating erectile dysfunction (ED), infertility, bodybuilding, cancer, weak bones (osteoporosis), and fungal and bacterial infections. Topically, Cnidium has been used in Traditional Chinese Medicine for thousands of years, often for skin conditions, and is a common ingredient in Chinese lotions, creams, and ointments. The herb's classical TCM properties include warming the kidney, expelling cold and dampness, and supporting Yang.

The fruit is known in Chinese as She Chuang Zi (蛇床子). Cnidium monnieri was described and the name published by Carl Linnaeus, and it was Pierre Cusson who reclassified it into today's valid botanical systematics in 1787.

3. Key Constituents and Phytochemistry

Osthole is the principal bioactive coumarin found in Cnidium monnieri fruit. Other coumarins found alongside it in C. monnieri include imperatorin and xanthotoxol. The relative proportions of these constituents vary with geographic origin, harvest time, and processing method. The structural identity of osthole — the prenylated side chain and methoxy substituent on the coumarin ring — is the basis for its distinct biological activity compared to simpler coumarins.

4. Mechanisms of Action

Overarching Mechanistic Themes

Pharmacokinetic studies showed osthole uptake and utilization are fast and efficient in the body; moreover, the mechanisms of multiple pharmacological activities of osthole are very likely related to its modulatory effect on cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels, though some mechanisms remain unclear. The regulatory effect of osthole on cAMP and cGMP levels and on some ion channels can be seen as contributing to several of its pharmacological properties, though the mechanisms underlying these properties have not been fully understood.

Anti-inflammatory Mechanisms

Osthole exhibits immunomodulatory and anti-inflammatory properties by regulating the expression of a series of key factors, including TNF-α, NF-κB, TGF-β, COX, NO, ERK, and JNK, involved in the process of immune response and other metabolic pathways.

The anti-inflammatory activity of osthole is mediated through multiple mechanisms involving inhibition of various transcription factors such as the NF-κB/MAPK pathway and down-regulation of pro-inflammatory cytokines such as TNF-α and IL-6. Research has established that osthole inhibited the production of NO, PGE2, TNF-α, and IL-6 in LPS-induced macrophages and suppressed the activity of iNOS and COX-2, probably by blocking the NF-κB and MAPK/p38 pathways.

Anticancer Mechanisms

Emerging evidence indicates that osthole can inhibit the proliferation, invasion, and metastasis of cancer cells through various mechanisms, including inducing apoptosis and autophagy, regulating the tumor microenvironment, inhibiting tumor angiogenesis, and enhancing the sensitivity of cancer cells to chemotherapy and radiotherapy.

Akt is a key downstream kinase of PI3K, and activation of the Akt pathway is a major mediator of cell proliferation, growth, survival, and angiogenesis in various cancers such as lung cancer, breast cancer, and gastric cancer; osthole has been reported to exert anticancer effects by inhibiting the PI3K/Akt pathway in various cancers. In endometrial cancer cell lines, osthole treatment induced JEC cell apoptosis and promoted the release of pro-apoptotic proteins Bax while activating cleaved caspase-3, caspase-9, and PARP; additionally, osthole significantly increased the expression of PTEN and decreased the phosphorylated form of PI3K and AKT in a concentration-dependent manner.

Neuroprotective Mechanisms

Osthole was identified as a modulator of the neurotransmitter gamma-aminobutyric acid (GABA-A) receptor in vitro, which provided a possible mechanism explaining its antiseizure effects. Multiple lines of evidence have demonstrated the protective effect of osthole on alleviating brain damage and improving neurobehavioral functions caused by both chronic and acute ischemia, due to its antioxidative and anti-inflammatory properties, acting through the mitogen-activated protein kinase (MAPK) pathway via prolonged activation of ERK1/2 and suppression of JNK activity.

Osthole has been shown to promote neural stem cell proliferation and neuronal differentiation while inhibiting apoptosis through the Wnt/β-catenin signaling pathway.

Osteogenic Mechanisms

In vitro findings revealed that osthole promoted osteoblast differentiation by activating Wnt/β-catenin signaling and subsequently increasing BMP2 expression. Results obtained after application of BMP-2 antagonists, p38 inhibitor, and ERK2 inhibitor indicated that the BMP-2/p38 pathway was associated with the early phase of osthole-induced osteoblast differentiation, whereas ERK2 was involved in the later phase of cellular ossification.

Osthole increases osteoblast-related bone formation and decreases osteoclast-related bone resorption, suppressing osteoporosis-related fragility fracture. Specifically, osthole attenuates osteoclast formation by stimulating the activation of β-catenin–OPG (osteoprotegerin) signaling.

Cardiovascular Mechanisms

Osthole, the main active constituent in Fructus Cnidii, has anti-inflammatory and anti-oxidant activities; apoptosis of vascular endothelial cells is an important cause of cardiovascular disease, and inflammation and oxidative stress are two key factors in endothelial cell injury. Research has shown that osthole remarkably attenuates angiotensin II-induced apoptosis of rat aortic endothelial cells (RAECs) via alleviating inflammation and oxidative stress.

Bronchodilatory Mechanisms

Researchers have found that osthole possesses potent airway-relaxation activity by inhibiting phosphodiesterase 4D (PDE4D) activity, making it a potential novel bronchodilator that does not target β2-adrenoceptors for asthma treatment.

5. Scientific Evidence by Area of Use

5.1 Cancer

Evidence base: Predominantly preclinical (in vitro and animal studies). No registered human clinical trials of osthole as a cancer treatment have been published as of the most recent comprehensive reviews.

Studies have reported a wide range of pharmacological activities of osthole, including anticancer effects across multiple cancer types, alongside anti-inflammatory, antioxidant, antipruritic, antiasthma, anti-osteoporosis, antibacterial and antiviral, immune regulatory, and fracture healing promoting activities.

A large number of studies have proven that osthole has an effective anticancer effect in various tissues, including gallbladder cancer, ovarian cancer, head and neck carcinoma, pancreatic cancer, esophageal squamous cell carcinoma, and breast cancer.

In lung cancer, osthole induces G2/M cell cycle arrest and apoptosis in lung cancer A549 cells by modulating the PI3K/Akt pathway. In a study of human laryngeal cancer and medulloblastoma cell lines, osthole decreased proliferation and cell viability of cancer cells in a dose-dependent manner; the compound induced apoptosis and increased cell numbers in G1 while decreasing cell numbers in S/G2 phases of the cell cycle.

In drug resistance, osthole could partially reverse cisplatin resistance in CD133-positive hepatocellular carcinoma (HCC) cells both in vitro and in vivo, and many studies have shown that osthole could increase the sensitivity to chemotherapy drugs.

Limitations: All published evidence in oncology is confined to cell culture models and rodent xenograft experiments. No human clinical data exist. The in vitro concentrations at which effects are observed are often pharmacologically high and may not be achievable safely in humans. Translation to human therapy remains unestablished.

5.2 Bone Health and Osteoporosis

Evidence base: Substantial preclinical (in vitro and animal) evidence; very limited clinical data in humans.

Osthole has been reported to inhibit osteoclast formation and function, promote osteoblast differentiation and bone formation, increase bone mineral density (BMD) and bone strength, and enhance fracture healing. Osthole, a coumarin-like derivative extracted from Chinese herbs, has been shown to stimulate osteoblast proliferation and differentiation; in one study, local injection of osthole significantly increased new bone formation on the surface of mouse calvaria.

Other reports found that osthole can prohibit osteoclast formation and partly ameliorate bone loss in nephrectomized mice by significantly increasing the expression of osteogenic differentiation-related factors and promoting osteoprotegerin (OPG) secretion and calcium salt deposition; this suggests that osthole has medicinal value in promoting osteoblast bone formation.

While osthole may become a promising agent to protect against osteoporosis development, more studies should be performed due to uncertainty of drug targets, and further pharmacological investigation of osthole in osteoporosis treatment might lead to the development of potential drug candidates.

Limitations: Evidence is almost entirely from cell culture and rodent models (including ovariectomized mice mimicking postmenopausal osteoporosis). Robust randomized controlled trials in humans have not been published.

5.3 Neuroprotection and Cognitive Function

Evidence base: Preclinical only (cell culture and animal models).

Pretreatment with osthole showed a significant protective effect on the viability of PC12 cells exposed to the neurotoxin MPP+, which is an in vitro model of Parkinson's disease. Osthole has also been suggested as a promising herbal component for memory loss therapy.

In Alzheimer's disease research, osthole, classified as a bioactive ingredient in many TCM formulas, has been demonstrated to effectively alleviate Alzheimer's disease (AD) symptoms in animal models; however, its low bioavailability in the brain has limited its clinical application. A pharmacological study found that the concentration of osthole in the cerebrospinal fluid increased almost tenfold after intranasal administration of osthole/borneol compared to oral administration in rats, illustrating efforts to improve central nervous system delivery.

Limitations: All neuroprotection evidence is derived from cellular or animal experiments. No human clinical trials have assessed osthole for any neurological condition.

5.4 Inflammation and Immune Modulation

Evidence base: Strong preclinical support; no human clinical trial evidence.

In 2019, Fan and co-workers evaluated in vivo and in vitro the anti-inflammatory activity of osthole, a natural prenylated coumarin from Cnidium monnieri that has shown neuroprotective, osteogenic, immunomodulatory, anticancer, hepatoprotective, cardiovascular protective, and antimicrobial properties. The research team established that osthole inhibited the production of NO, PGE2, TNF-α, and IL-6 in LPS-induced macrophages and suppressed the activity of iNOS and COX-2, probably by blocking the NF-κB and MAPK/p38 pathways.

Limitations: Immune-modulatory and anti-inflammatory findings are restricted to in vitro macrophage studies and rodent inflammation models. No human data on inflammatory endpoints are available.

5.5 Cardiovascular Protection

Evidence base: Preclinical only.

Plenty of studies reveal that osthole exerts a powerful reactive oxygen species (ROS) scavenging effect with potent anti-inflammatory effects; its anti-inflammatory activity is mediated through inhibition of NF-κB/MAPK pathways and down-regulation of pro-inflammatory cytokines such as TNF-α and IL-6. In vitro and in vivo experimental results have revealed that osthole demonstrates multiple pharmacological actions including cardiovascular protective activity.

Limitations: Evidence is limited to cell-based and animal studies. Human cardiovascular outcome studies have not been conducted.

5.6 Hepatoprotection

Evidence base: Preclinical (rodent trauma-hemorrhage models and cell-based assays).

In vitro and in vivo experimental results have revealed that osthole demonstrates hepatoprotective activity in multiple experimental models. Research has examined osthole's ability to attenuate hepatic injury in rodent models of trauma-hemorrhage, with anti-inflammatory mechanisms through p38 MAPK pathway modulation implicated in the observed protection.

Limitations: No controlled clinical data in humans. Moreover, at higher doses, osthole itself has been shown to pose a hepatotoxicity concern (see Safety section).

5.7 Asthma and Respiratory Function

Evidence base: Mechanistic/preclinical.

Extensive studies have shown that osthole exhibits many medicinal properties, and researchers have found that it possesses potent airway-relaxation activity by inhibiting phosphodiesterase 4D activity, making it a potential novel bronchodilator that does not target β2-adrenoceptors for asthma treatment.

Limitations: The bronchodilatory evidence is mechanistic and preclinical. No human asthma clinical trials of osthole have been published.

5.8 Skin Conditions and Antipruritic Effects

Evidence base: Traditional use is well-established; some pharmacological support from preclinical studies.

Cnidium monnieri has been used in Traditional Chinese Medicine for thousands of years, often for skin conditions; it is a common ingredient in Chinese lotions, creams, and ointments. Among the pharmacological activities reported for osthole are antipruritic effects.

Limitations: Human clinical evidence specific to osthole for dermatological indications is lacking.

5.9 Antimicrobial Activity

Evidence base: Preclinical.

Among the potential pharmacological activities identified for osthole is antiparasitic and antimicrobial activity. The main active components in C. monnieri are coumarins, principally osthole, and volatile compounds exhibiting multiple pharmacological effects including antibacterial effects.

Limitations: Antimicrobial activity is demonstrated in cell-based assays and in limited animal work. No clinical trials in humans have examined osthole for infectious disease indications.

6. Pharmacokinetics

New evidence shows that osthole induces a sequence of therapeutic actions and has a moderate absorption rate and rapid metabolic characteristics. Pharmacokinetic studies showed osthole uptake and utilization are fast and efficient in the body.

A major limiting factor for osthole's clinical development is its poor aqueous solubility. The low water solubility of osthole limits its potential clinical application. Its pharmacological effects are limited in the human body because of poor solubility and bioavailability.

Various advanced drug delivery systems have been studied to address these limitations. Osthole-PBCA nanoparticles were found to be spherical, with good dispersion, small particle size, and a good polydispersity index; drugs in the nanoparticle formulation showed better stability and sustained release; the nanoparticles displayed significantly enhanced intracellular uptake and cytotoxicity compared with free osthole, and in vivo pharmacokinetic studies revealed that the AUC of osthole nanoparticles was higher than that of free osthole.

For intranasal delivery aimed at the central nervous system, the concentration of osthole in the cerebrospinal fluid increased almost tenfold after intranasal administration of an osthole/borneol gel compared to oral administration in rats.

7. Dosage Forms and Reported Dosages

Osthole is available in research and supplement contexts as a standardized extract of Cnidium monnieri fruit (typically standardized to a defined percentage of osthole), as well as as a purified isolate for laboratory and pharmacological research. Osthole (often referred to as osthol, 7-methoxy-8-(3-methyl-2-butenyl) coumarin) is a coumarin analog initially isolated from the Cnidium plant.

Dosages reported in preclinical research:

• In lung cancer A549 cell studies, cells were treated with osthole concentrations of 0, 50, 100, and 150 μM for 48 hours for PI3K/Akt pathway assessment.
• In retinoblastoma cell line (Y-79) studies, osthole was used at an IC50 of 200 μM for 24-hour treatment and 120 μM for 48-hour treatment, significantly altering the PI3K/AKT/mTOR pathway.
• In glioblastoma cell line studies, an osthole concentration of 150 μM was identified as the most efficient and initiated apoptosis in approximately the greatest proportion of treated cells.

It must be emphasized that these are in vitro cell culture dosages and do not translate directly to human dosing. No consensus clinical dosage for osthole as a supplement has been established through human trials, and Cnidium is most commonly used for increasing sexual performance and sex drive, erectile dysfunction, and skin conditions, but there is no good scientific evidence to support any of its uses in humans.

8. Safety Considerations and Drug Interactions

General Safety Profile

While a wide range of pharmacological activities has been reported for osthole, it is characterized by rare toxic side effects and a broad safety range in preclinical evaluations, which has contributed to its development prospects. However, important safety signals have emerged from preclinical toxicological studies.

Hepatotoxicity

New evidence shows that osthole has a moderate absorption rate and rapid metabolic characteristics; however, this phytoconstituent possesses potential hepatotoxicity, and caution should be exercised against the risk of drug combination.

Kidney as a Target Organ

In safety assessment studies, a number of significant clinical and pathological changes were associated with the subchronic oral administration of osthole to Wistar rats, and several observations support the conclusion that the kidney is a plausible target organ.

CYP450 Enzyme Modulation and Drug Interactions

The CYP450 enzyme system is among the most important xenobiotic-biotransformation systems with high catalytic potential; it detoxifies xenobiotics or activates them to reactive intermediates; the highest levels of CYP enzymes are found in the liver endoplasmic reticulum; by inducing CYP450, one drug can stimulate the metabolism of a second drug and thereby decrease or ameliorate its clinical effects; various compounds modulate isozymes of the monooxygenases to cause significant drug interactions; previous studies have shown that naturally occurring coumarins are able to modulate xenobiotic metabolizing enzymes.

The interaction with CYP enzymes raises the possibility that osthole, when combined with pharmaceutical drugs metabolized by these enzymes, could alter drug plasma concentrations in clinically meaningful ways. The extent and clinical relevance of specific osthole–drug interactions in humans has not been adequately characterized in clinical pharmacokinetic studies.

Reproductive Concerns

Preclinical data have raised potential concerns regarding use during pregnancy. Traditional TCM practice has contraindicated Cnidium monnieri (and by extension, osthole-containing preparations) during pregnancy.

Bioavailability Challenges as a Safety Consideration

The pharmacological mechanism, pharmacokinetics, and toxicological effects of osthole are far from clear, and the potential drug delivery platforms of osthole remain to be comprehensively delineated. This uncertainty makes it difficult to predict the safety profile across different formulations and doses in human populations.

9. Current Research Status and Evidence Summary

Experimental results demonstrate that osthole exhibits a variety of pharmacological benefits including neuroprotection, osteogenesis, immunomodulation, and cancer-combating properties, making it a potential multitarget complementary medicine and functional food. In vitro and in vivo experimental results have revealed that osthole demonstrates multiple pharmacological actions including neuroprotective, osteogenic, immunomodulatory, anticancer, hepatoprotective, cardiovascular protective, and antimicrobial activities.

Nonetheless, the critical gap in the literature is the near-complete absence of human clinical trial data. The therapeutic benefits of osthole ought to be elucidated in a greater array of comprehensive research studies, and the molecular mechanisms underlying these benefits should be explored. More studies should be performed due to the uncertainty of drug targets; further pharmacological investigation of osthole in treatment might lead to the development of potential drug candidates.

Osthole has shown many biological properties, including anticancer, anti-inflammatory, osteogenic, and neuroprotective activities, without significant toxic side effects in preclinical settings. However, the totality of evidence for therapeutic use in humans remains preliminary. The compound is an active area of pharmaceutical research, with studies directed toward solving its formulation challenges and translating its well-characterized preclinical activities into clinical applications.

References

• Osthole: An overview of its sources, biological activities, and modification development — PMC (2021)
• Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine — PMC (2015)
• Osthole, a Coumarin from Cnidium monnieri: A Review on Its Pharmacology, Pharmacokinetics, Safety, and Innovative Drug Delivery Platforms — PubMed / Am J Chin Med (2024)
• Osthole: An up-to-date review of its anticancer potential and mechanisms of action — PMC / Frontiers in Pharmacology (2022)
• Osthole: An up-to-date review of its anticancer potential and mechanisms of action — Frontiers in Pharmacology (2022)
• Review on the protective activity of osthole against the pathogenesis of osteoporosis — Frontiers in Pharmacology (2023)
• Osthole Stimulates Osteoblast Differentiation and Bone Formation by Activation of β-Catenin–BMP Signaling — PMC (2011)
• Osthole enhances bone mass of senile osteoporosis and stimulates osteoprotegerin expression by activating β-catenin signaling — PubMed (2021)
• High-Throughput Metabolomics Discovers Metabolic Biomarkers and Pathways Evaluating the Efficacy of Osthole Against Osteoporosis — PMC (2020)
• Review on the protective activity of osthole against the pathogenesis of osteoporosis — PMC (2023)
• Osthole suppresses proliferation and induces apoptosis via inhibiting PI3K/AKT signaling in endometrial cancer JEC cells — PMC (2021)
• Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma — PMC (2017)
• Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway — J Exp Clin Cancer Res (2011)
• Anticancer potential of osthole: targeting gynecological tumors and breast cancer — Pharmacological Reports / Springer (2024)
• Osthole Induces Apoptosis, Suppresses Cell-Cycle Progression and Proliferation of Cancer Cells — Anticancer Research (2014)
• Osthole protects against Ang II-induced endotheliocyte death by targeting NF-κB pathway and Keap-1/Nrf2 pathway — PMC (2019)
• Osthole Attenuates Hepatic Injury in a Rodent Model of Trauma-Hemorrhage — PMC (2013)
• Osthole/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP/PS1 transgenic mice — PMC (2023)
• Biosynthesis of the Plant Coumarin Osthole by Engineered Saccharomyces cerevisiae — PubMed (2023)
• Osthole-loaded N-octyl-O-sulfonyl chitosan micelles (NSC-OST) inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in rats — PMC (2020)
• Design, Preparation, and Evaluation of Osthol Poly-Butyl-Cyanoacrylate Nanoparticles with Improved In Vitro Anticancer Activity in Neuroblastoma Treatment — PMC (2022)
• Safety Assessment of Osthole Isolated from Prangos ferulacea: Acute and Subchronic Toxicities and Modulation of Cytochrome P450 — Jundishapur J Nat Pharm Prod (2017)
• An Overview of Coumarin as a Versatile and Readily Accessible Scaffold with Broad-Ranging Biological Activities — PMC (2020)
• Cnidium monnieri — Wikipedia (botanical reference)
• Cnidium: Health Benefits, Side Effects, Uses, Dose & Precautions — RxList
• Osthole: A Coumarin with Dual Roles in Biology and Chemistry — Biology (MDPI, 2025)
• Osthole: A Coumarin with Dual Roles in Biology and Chemistry — PMC (2025)